Confusion reigns as industry resists and challenges CMC labelling decision
This article was originally published in Clinica
Executive Summary
The medtech labelling decision made by the Central Management Committee, the year-old committee comprising competent authority representatives, has angered the medtech industry and led to questions over the legitimacy not only of this decision, but of all judgements made by this group.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.
First Public Discussion On How EU Medtech Regulatory Governance Structure May Evolve
Does the EU need a medtech agency for the first time in its history? Nothing can or should be decided too quickly but five high-profile experts broadly agreed that change is now critical.